MedTrace Logo

Autologous Platelet-Rich Plasma Intra-ovarian Infusion in Poor Responders

NCT03937661 · Status: RECRUITING · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2024-12-27

No results posted yet for this study

Summary

Autologous PRP intra ovarian infusion may improve ovarian response, patients' hormonal profile as well as fresh embryo transfer (ET)-ICSI cycles' outcome in patients presenting with Poor Ovarian Response (POR).

Conditions

  • Ovary; Anomaly
  • Infertility, Female

Interventions

BIOLOGICAL

PRP

Autologous PRP intra ovarian infusion

BIOLOGICAL

Placebo

Autologous PFP intra ovarian infusion

Sponsors & Collaborators

  • National and Kapodistrian University of Athens

    collaborator OTHER

  • Genesis Athens Clinic

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
35 Years
Max Age
47 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-05-06
Primary Completion
2025-01-30
Completion
2025-08-30

Countries

  • Greece

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03937661 on ClinicalTrials.gov